John Rhoden

John Rhoden is an accomplished professional in the field of chemical engineering, holding a Doctor of Philosophy (PhD) from the Massachusetts Institute of Technology. With extensive experience in the pharmaceutical and biotechnology industries, Rhoden served as Executive Director at Eli Lilly and Company from October 2012 to April 2020, where leadership was provided for genetic medicines ADME projects. After this role, Rhoden continued to excel at Fusion Pharmaceuticals as Senior Director of Preclinical Development and later as Director of Preclinical Development until November 2023. In December 2023, Rhoden took on the position of Head of Research at Matrisome Bio. Earlier academic contributions include significant research on the penetration of therapeutic antibodies into solid tumors while pursuing a PhD, and engagement as a Research Assistant during undergraduate studies at North Carolina State University, where a B.S. in Chemical Engineering was earned.